Gilead Historical Financial Ratios

GILD Stock

USD 96.95 1.36 1.42%

Gilead Sciences is recently reporting on over 113 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 7.87 or Days Sales Outstanding of 68.53 will help investors to properly organize and evaluate Gilead Sciences financial condition quickly.

Quick Ratio Current Ratio

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

About Gilead Financial Ratios Analysis

Gilead SciencesFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Gilead Sciences investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Gilead financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Gilead Sciences history.

Gilead Sciences Financial Ratios Chart

At present, Gilead Sciences' Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Free Cash Flow Yield is expected to grow to 0.07, whereas Dividend Yield is forecasted to decline to 0.03.

Price To Sales Ratio Dividend Yield Ptb Ratio Days Sales Outstanding

Add Fundamental

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Gilead Sciences stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Gilead Sciences sales, a figure that is much harder to manipulate than other Gilead Sciences multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Dividend Yield

Dividend Yield is Gilead Sciences dividend as a percentage of Gilead Sciences stock price. Gilead Sciences dividend yield is a measure of Gilead Sciences stock productivity, which can be interpreted as interest rate earned on an Gilead Sciences investment. A financial ratio that shows how much a company pays out in dividends each year relative to its stock price, calculated as annual dividends per share divided by price per share.

Ptb Ratio

Price-to-Book ratio, a financial valuation metric used to compare a company's current market price to its book value. It provides insight into the value that market participants place on the company's equity relative to its net asset value.

Most ratios from Gilead Sciences' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Gilead Sciences current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Gilead Sciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.At present, Gilead Sciences' Book Value Per Share is projected to increase significantly based on the last few years of reporting. The current year's Free Cash Flow Yield is expected to grow to 0.07, whereas Dividend Yield is forecasted to decline to 0.03.

	2022	2023	2024	2025 (projected)
Dividend Yield	0.0344	0.0377	0.0339	0.0268
Price To Sales Ratio	3.95	3.73	4.29	4.07

Dividend Yield Price To Sales Ratio

Gilead Sciences fundamentals Correlations

	Price To Sales Ratio	Dividend Yield	Ptb Ratio	Days Sales Outstanding	Book Value Per Share	Free Cash Flow Yield	Operating Cash Flow Per Share	Capex To Depreciation	Pb Ratio	Ev To Sales	Free Cash Flow Per Share	Roic	Inventory Turnover	Net Income Per Share	Days Of Inventory On Hand	Payables Turnover	Capex To Revenue	Cash Per Share	Pocfratio	Interest Coverage	Payout Ratio	Capex To Operating Cash Flow	Pfcf Ratio	Days Payables Outstanding	Income Quality	Roe
Price To Sales Ratio		-0.33	0.88	1.0	-0.64	-0.64	-0.49	-0.11	0.88	1.0	-0.48	-0.65	-0.36	-0.35	0.77	-0.57	0.99	-0.32	-0.94	-0.37	-0.09	-0.88	-0.92	-0.69	-0.09	-0.59
Dividend Yield	-0.33		-0.6	-0.3	0.79	0.31	0.27	-0.41	-0.6	-0.32	0.24	-0.31	0.39	-0.15	-0.47	0.69	-0.27	0.38	0.18	-0.53	0.47	0.4	0.16	-0.31	0.46	-0.29
Ptb Ratio	0.88	-0.6		0.87	-0.7	-0.7	-0.43	-0.06	1.0	0.88	-0.41	-0.36	-0.43	-0.17	0.74	-0.59	0.83	-0.49	-0.74	-0.04	-0.19	-0.84	-0.71	-0.51	-0.18	-0.35
Days Sales Outstanding	1.0	-0.3	0.87		-0.62	-0.62	-0.47	-0.12	0.87	1.0	-0.46	-0.66	-0.35	-0.35	0.76	-0.55	0.99	-0.31	-0.95	-0.38	-0.07	-0.89	-0.94	-0.7	-0.08	-0.6
Book Value Per Share	-0.64	0.79	-0.7	-0.62		0.52	0.64	-0.35	-0.7	-0.64	0.61	0.17	0.6	0.35	-0.83	0.86	-0.6	0.48	0.49	-0.1	0.1	0.6	0.47	-0.09	0.09	0.2
Free Cash Flow Yield	-0.64	0.31	-0.7	-0.62	0.52		0.83	0.01	-0.7	-0.65	0.83	0.58	0.33	0.63	-0.61	0.26	-0.62	0.51	0.41	0.41	0.11	0.37	0.36	0.37	0.11	0.67
Operating Cash Flow Per Share	-0.49	0.27	-0.43	-0.47	0.64	0.83		-0.09	-0.43	-0.49	1.0	0.61	0.36	0.86	-0.62	0.33	-0.48	0.44	0.29	0.49	0.0	0.23	0.25	0.06	0.0	0.71
Capex To Depreciation	-0.11	-0.41	-0.06	-0.12	-0.35	0.01	-0.09		-0.06	-0.11	-0.09	0.28	-0.18	0.05	0.18	-0.49	-0.03	0.05	0.17	0.21	-0.08	0.33	0.19	0.55	-0.07	0.26
Pb Ratio	0.88	-0.6	1.0	0.87	-0.7	-0.7	-0.43	-0.06		0.88	-0.41	-0.36	-0.43	-0.17	0.74	-0.59	0.83	-0.49	-0.74	-0.04	-0.19	-0.84	-0.71	-0.51	-0.18	-0.35
Ev To Sales	1.0	-0.32	0.88	1.0	-0.64	-0.65	-0.49	-0.11	0.88		-0.48	-0.66	-0.36	-0.36	0.77	-0.56	0.99	-0.32	-0.94	-0.38	-0.08	-0.88	-0.92	-0.69	-0.08	-0.6
Free Cash Flow Per Share	-0.48	0.24	-0.41	-0.46	0.61	0.83	1.0	-0.09	-0.41	-0.48		0.62	0.34	0.87	-0.61	0.31	-0.47	0.42	0.28	0.51	-0.01	0.21	0.24	0.07	-0.01	0.72
Roic	-0.65	-0.31	-0.36	-0.66	0.17	0.58	0.61	0.28	-0.36	-0.66	0.62		0.08	0.78	-0.46	0.06	-0.68	0.13	0.62	0.91	-0.22	0.4	0.6	0.66	-0.21	0.98
Inventory Turnover	-0.36	0.39	-0.43	-0.35	0.6	0.33	0.36	-0.18	-0.43	-0.36	0.34	0.08		0.21	-0.82	0.51	-0.31	0.73	0.24	-0.02	-0.2	0.35	0.22	-0.1	-0.2	0.11
Net Income Per Share	-0.35	-0.15	-0.17	-0.35	0.35	0.63	0.86	0.05	-0.17	-0.36	0.87	0.78	0.21		-0.48	0.15	-0.36	0.25	0.23	0.7	-0.34	0.09	0.2	0.15	-0.34	0.87
Days Of Inventory On Hand	0.77	-0.47	0.74	0.76	-0.83	-0.61	-0.62	0.18	0.74	0.77	-0.61	-0.46	-0.82	-0.48		-0.75	0.73	-0.6	-0.63	-0.24	0.16	-0.65	-0.6	-0.19	0.16	-0.46
Payables Turnover	-0.57	0.69	-0.59	-0.55	0.86	0.26	0.33	-0.49	-0.59	-0.56	0.31	0.06	0.51	0.15	-0.75		-0.55	0.16	0.47	-0.17	0.02	0.52	0.45	-0.13	0.01	0.04
Capex To Revenue	0.99	-0.27	0.83	0.99	-0.6	-0.62	-0.48	-0.03	0.83	0.99	-0.47	-0.68	-0.31	-0.36	0.73	-0.55		-0.24	-0.95	-0.42	-0.07	-0.82	-0.93	-0.7	-0.07	-0.61
Cash Per Share	-0.32	0.38	-0.49	-0.31	0.48	0.51	0.44	0.05	-0.49	-0.32	0.42	0.13	0.73	0.25	-0.6	0.16	-0.24		0.17	0.02	-0.07	0.33	0.15	0.03	-0.07	0.21
Pocfratio	-0.94	0.18	-0.74	-0.95	0.49	0.41	0.29	0.17	-0.74	-0.94	0.28	0.62	0.24	0.23	-0.63	0.47	-0.95	0.17		0.35	0.04	0.87	1.0	0.75	0.04	0.52
Interest Coverage	-0.37	-0.53	-0.04	-0.38	-0.1	0.41	0.49	0.21	-0.04	-0.38	0.51	0.91	-0.02	0.7	-0.24	-0.17	-0.42	0.02	0.35		-0.16	0.08	0.33	0.51	-0.15	0.88
Payout Ratio	-0.09	0.47	-0.19	-0.07	0.1	0.11	0.0	-0.08	-0.19	-0.08	-0.01	-0.22	-0.2	-0.34	0.16	0.02	-0.07	-0.07	0.04	-0.16		0.13	0.03	-0.03	1.0	-0.26
Capex To Operating Cash Flow	-0.88	0.4	-0.84	-0.89	0.6	0.37	0.23	0.33	-0.84	-0.88	0.21	0.4	0.35	0.09	-0.65	0.52	-0.82	0.33	0.87	0.08	0.13		0.87	0.61	0.13	0.32
Pfcf Ratio	-0.92	0.16	-0.71	-0.94	0.47	0.36	0.25	0.19	-0.71	-0.92	0.24	0.6	0.22	0.2	-0.6	0.45	-0.93	0.15	1.0	0.33	0.03	0.87		0.75	0.03	0.49
Days Payables Outstanding	-0.69	-0.31	-0.51	-0.7	-0.09	0.37	0.06	0.55	-0.51	-0.69	0.07	0.66	-0.1	0.15	-0.19	-0.13	-0.7	0.03	0.75	0.51	-0.03	0.61	0.75		-0.02	0.58
Income Quality	-0.09	0.46	-0.18	-0.08	0.09	0.11	0.0	-0.07	-0.18	-0.08	-0.01	-0.21	-0.2	-0.34	0.16	0.01	-0.07	-0.07	0.04	-0.15	1.0	0.13	0.03	-0.02		-0.25
Roe	-0.59	-0.29	-0.35	-0.6	0.2	0.67	0.71	0.26	-0.35	-0.6	0.72	0.98	0.11	0.87	-0.46	0.04	-0.61	0.21	0.52	0.88	-0.26	0.32	0.49	0.58	-0.25

Click cells to compare fundamentals

Gilead Sciences Account Relationship Matchups

Gilead Sciences fundamentals Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Price To Sales Ratio	2.97	3.34	3.95	3.73	4.29	4.07
Dividend Yield	0.0471	0.0395	0.0344	0.0377	0.0339	0.0268
Ptb Ratio	4.02	4.33	5.08	4.43	5.09	7.87
Days Sales Outstanding	72.32	60.06	63.91	62.73	72.14	68.53
Book Value Per Share	14.5	16.77	16.9	18.23	16.41	17.23
Operating Cash Flow Per Share	6.5	9.06	7.23	6.42	5.77	6.06
Stock Based Compensation To Revenue	0.0283	0.026	0.0233	0.0282	0.0325	0.027
Pb Ratio	4.02	4.33	5.08	4.43	5.09	7.87
Ev To Sales	4.0	4.12	4.68	4.43	5.09	4.83
Free Cash Flow Per Share	5.98	8.6	6.65	5.95	5.35	5.62
Roic	0.082	0.006271	0.0959	0.11	0.12	0.0627
Inventory Turnover	1.52	2.41	2.01	3.64	3.27	3.44
Net Income Per Share	0.0708	4.96	3.66	4.54	4.09	4.29
Days Of Inventory On Hand	240.62	151.18	181.95	100.38	115.43	109.66
Payables Turnover	5.42	9.36	6.25	11.81	10.63	11.16
Research And Ddevelopement To Revenue	0.23	0.41	0.2	0.26	0.29	0.28
Capex To Revenue	0.0263	0.0212	0.0267	0.0216	0.0248	0.0236
Cash Per Share	5.89	5.19	5.09	5.82	5.24	3.08
Pocfratio	8.97	8.01	11.88	12.63	11.37	11.93
Interest Coverage	7.14	7.4	7.84	8.06	9.26	8.8
Payout Ratio	38.75	0.58	0.81	0.67	0.61	0.57
Capex To Operating Cash Flow	0.0796	0.0509	0.0802	0.0731	0.0658	0.0691
Pfcf Ratio	9.74	8.44	12.91	13.62	12.26	12.87
Days Payables Outstanding	67.38	38.98	58.39	30.89	27.8	29.19
Income Quality	91.78	1.84	1.99	1.43	1.28	1.22
Roe	0.25	0.24	0.004884	0.3	0.22	0.12
Ev To Operating Cash Flow	12.08	9.89	14.06	14.99	13.49	14.16
Pe Ratio	822.84	14.65	23.46	17.85	16.06	20.43
Ev To Free Cash Flow	13.12	10.42	15.29	16.17	14.55	15.28
Earnings Yield	0.001215	0.0683	0.0426	0.056	0.0504	0.053
Net Debt To E B I T D A	6.15	1.89	2.24	1.8	2.07	1.24
Current Ratio	1.39	1.3	1.36	1.43	1.64	1.56
Tangible Book Value Per Share	(18.31)	(16.5)	(12.75)	(9.63)	(11.08)	(10.52)
Receivables Turnover	5.05	6.08	5.71	5.82	5.24	3.9
Graham Number	4.81	43.25	37.3	43.23	38.9	40.85

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

When determining whether Gilead Sciences is a strong investment it is important to analyze Gilead Sciences' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Gilead Sciences' future performance. For an informed investment choice regarding Gilead Stock, refer to the following important reports:

How To Invest In Gilead

Details

Is Gilead Stock a good investment?

Details

What is Gilead Sciences' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Gilead Stock refer to our How to Trade Gilead Stock guide.

You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Gilead Sciences. If investors know Gilead will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Gilead Sciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.42)

Dividend Share

3.06

Earnings Share

0.09

Revenue Per Share

22.703

Quarterly Revenue Growth

0.07

The market value of Gilead Sciences is measured differently than its book value, which is the value of Gilead that is recorded on the company's balance sheet. Investors also form their own opinion of Gilead Sciences' value that differs from its market value or its book value, called intrinsic value, which is Gilead Sciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Gilead Sciences' market value can be influenced by many factors that don't directly affect Gilead Sciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Gilead Sciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Gilead Sciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Gilead Sciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Price To Sales Ratio	Dividend Yield
Ptb Ratio	Days Sales Outstanding
Book Value Per Share	Free Cash Flow Yield
Invested Capital	Operating Cash Flow Per Share
Average Payables	Stock Based Compensation To Revenue
Capex To Depreciation	Pb Ratio
Ev To Sales	Free Cash Flow Per Share
Roic	Inventory Turnover
Net Income Per Share	Days Of Inventory On Hand
Payables Turnover	Sales General And Administrative To Revenue
Average Inventory	Research And Ddevelopement To Revenue
Capex To Revenue	Cash Per Share
Pocfratio	Interest Coverage
Payout Ratio	Capex To Operating Cash Flow
Pfcf Ratio	Days Payables Outstanding
Net Current Asset Value	Income Quality
Roe	Tangible Asset Value
Ev To Operating Cash Flow	Pe Ratio
Return On Tangible Assets	Ev To Free Cash Flow
Earnings Yield	Intangibles To Total Assets
Net Debt To E B I T D A	Current Ratio
Tangible Book Value Per Share	Receivables Turnover
Graham Number	Shareholders Equity Per Share
Debt To Equity	Capex Per Share
Graham Net Net	Average Receivables
Revenue Per Share	Interest Debt Per Share
Debt To Assets	Enterprise Value Over E B I T D A
Short Term Coverage Ratios	Price Earnings Ratio
Operating Cycle	Price Book Value Ratio
Price Earnings To Growth Ratio	Days Of Payables Outstanding
Dividend Payout Ratio	Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio	Pretax Profit Margin
Ebt Per Ebit	Operating Profit Margin
Effective Tax Rate	Company Equity Multiplier
Long Term Debt To Capitalization	Total Debt To Capitalization
Return On Capital Employed	Debt Equity Ratio
Ebit Per Revenue	Quick Ratio
Dividend Paid And Capex Coverage Ratio	Net Income Per E B T
Cash Ratio	Cash Conversion Cycle
Operating Cash Flow Sales Ratio	Days Of Inventory Outstanding
Days Of Sales Outstanding	Free Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage Ratios	Price To Book Ratio
Fixed Asset Turnover	Capital Expenditure Coverage Ratio
Price Cash Flow Ratio	Enterprise Value Multiple
Debt Ratio	Cash Flow To Debt Ratio
Price Sales Ratio	Return On Assets
Asset Turnover	Net Profit Margin
Gross Profit Margin	Price Fair Value
Return On Equity

Gilead Historical Financial Ratios

About Gilead Financial Ratios Analysis

Gilead Sciences Financial Ratios Chart

Price To Sales Ratio

Dividend Yield

Ptb Ratio

Gilead Sciences fundamentals Correlations

Gilead Sciences Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Gilead Sciences fundamentals Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Days Sales Outstanding	+ 1.0	Price To Sales Ratio
Ev To Sales	+ 1.0	Price To Sales Ratio
Pb Ratio	+ 1.0	Ptb Ratio
Ev To Sales	+ 1.0	Days Sales Outstanding
Free Cash Flow Per Share	+ 1.0	Operating Cash Flow Per Share
Pfcf Ratio	+ 1.0	Pocfratio

Pocfratio	- 0.95	Capex To Revenue
Pocfratio	- 0.95	Days Sales Outstanding
Pocfratio	- 0.94	Ev To Sales
Pfcf Ratio	- 0.94	Days Sales Outstanding
Pocfratio	- 0.94	Price To Sales Ratio
Pfcf Ratio	- 0.93	Capex To Revenue